a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
b Center for Bioinformatics and Molecular Medicine , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Expert Rev Clin Immunol. 2019 Jun;15(6):629-637. doi: 10.1080/1744666X.2019.1593141. Epub 2019 Mar 25.
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies production and immune complex deposition with systemic clinical manifestations. Interleukin (IL)-17-producing cells play a crucial role in disease pathogenesis and represent an attractive therapeutic target. Areas covered: This review provides an update on the possibility of targeting IL-17 in SLE. The rational for this approach as well as currently available and future targets are discussed. Expert opinion: Although human expression studies and animal models indicate that IL-17 blocking may be a promising therapeutic strategy for SLE, direct evidence for IL-17 inhibition in SLE patients is unavailable. Biologic therapies and small-molecule drugs that target IL-17 production are required for the achievement of a favorable clinical effect in SLE patients.
系统性红斑狼疮（SLE）是一种自身免疫性疾病，其特征是产生自身抗体和免疫复合物沉积，并伴有全身临床表现。白细胞介素（IL）-17 产生细胞在疾病发病机制中起关键作用，是一个有吸引力的治疗靶点。
本文综述了针对 SLE 中 IL-17 的靶向治疗的可能性。讨论了这种方法的合理性，以及目前可用和未来的靶点。
虽然人类表达研究和动物模型表明阻断 IL-17 可能是 SLE 的一种有前途的治疗策略，但 SLE 患者中 IL-17 抑制的直接证据尚不可用。需要针对 IL-17 产生的生物疗法和小分子药物，才能在 SLE 患者中实现良好的临床效果。
